About the Company
welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $APTX News
All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy
Aptinyx Inc. (APTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Aptinyx Inc. Common Stock (APTX)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of ...
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company ...
Patrick G Enright's Net Worth
Inc., Aptinyx Inc., Aimmune Therapeutics, Inc., and SEQUENOM INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to ...
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
Aptinyx Inc. APTX has an Earnings ESP of +19.23% and a Zacks Rank of 2. APTX has an estimated growth rate of 42.6% for 2024. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakthrough Study on Post-Traumatic Stress Disorder
The Psychiatric Genetics Consortium (PGC), a consortium of researchers led by scientists at University of California San ...
New Leaf Ventures III, L.P.'s Net Worth
Inc., Iterum Therapeutics plc, and Aptinyx Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks ...
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34%
The worst performers were Aptinyx Inc (NASDAQ:APTX) which was down 39.00% to 0.06 in late trade, NanoString Technologies Inc (NASDAQ:NSTG) which lost 29.02% to settle at 6.04 and Rigel ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Apple Inc. (AAPL)
Shares of Apple (AAPL) are trading lower after Needham's Laura Martin lowered estimates for the tech giant to reflect iPhone sales concerns and weakness in China. The estimates are offset by ...
AT&T Inc. (T)
Data breaches like the recent one involving millions of AT&T customers are becoming an almost regular occurrence. As more of our lives move online, our personal data like email addresses, phone ...
Loading the latest forecasts...